believe trial semaglutide triaL - Safety and efficacy of bimagrumab andsemaglutidein adults who are overweight or obese BELIEVE The BELIEVE Trial: Revolutionizing Weight Loss with Semaglutide and Bimagrumab

GLP-1 muscle loss study The pursuit of effective weight management solutions has taken a significant leap forward with the BELIEVE trial, investigating the combined efficacy of semaglutide and bimagrumab.Interim Results from Ongoing Phase 2 COURAGE Trial ... This groundbreaking research focuses on a critical aspect often overlooked in weight loss: preserving muscle mass while effectively reducing fat.Semaglutide2.4 mg over 52 weeks yields about 60% fat mass loss and 40% lean soft tissue loss; Tirzepatide over 72 weeks shows 74% fat mass loss and 25% lean ... Emerging data from the BELIEVE trial suggest a promising future for individuals struggling with overweight and obesity, offering a pathway to not only shed pounds but to do so in a healthier, more sustainable manner.

Recent findings presented at various medical conferences in 2025 highlight the success of this combination therapyBELIEVE study to assess Bimagrumab as treatment for .... The BELIEVE Phase 2b trial, a randomized, double-blind, placebo-controlled study, enrolled approximately 500 participants across 26 centers in the United States, Australia, and New Zealand. These participants were evaluated over a 72-week period to assess the impact of semaglutide (administered subcutaneously) combined with intravenous bimagrumab.BELIEVE Study Design—A Multinational, Double-Blind ... The study's design specifically aimed to understand how this combination therapy could influence body compositionThis study investigates if bimagrumab in addition tosemaglutideis able to preserve/increase muscle mass in the presence of weight and/or fat mass loss..

One of the most compelling outcomes from the BELIEVE study is the significant reduction in fat mass observed in participants receiving the bimagrumab and semaglutide combination. Reports indicate an approximate 70% reduction in fat mass without a commensurate loss of fat-free mass. This contrasts with some other weight loss approaches, where a substantial percentage of weight loss can be attributed to lean muscle tissue. For instance, some studies on semaglutide monotherapy over 52 weeks have shown a roughly 60% fat mass loss alongside a 40% lean soft tissue loss, underscoring the potential advantage of the combined approach.

Bimagrumab, an activin type II receptor-targeted antibody, plays a crucial role in promoting muscle growth.2025年6月2日—Thetrialdemonstrated that approximately 35% ofsemaglutide-induced ... Words such as “anticipate,” “expect,” “intend,” “plan,” “believe... By combining its muscle-preserving capabilities with the potent appetite-suppressing and glucose-regulating effects of semaglutide, researchers are achieving a nuanced approach to weight loss. Experts believe this synergy is key to achieving a higher quality of weight loss, where the loss is primarily composed of adipose tissue while essential muscle mass is maintained or even increasedSemaglutide and cardiovascular outcomes by baseline .... Earlier data from precursor studies have hinted at a 20.5% decline in fat mass and a 3.6% increase in lean mass with similar interventionsInterim Results from Ongoing Phase 2 COURAGE Trial ....

The BELIEVE trial's methodology is robust, characteristic of a well-designed trialChallenges and promising outcomes for fat loss and ... - PMC. Participants received either a placebo or bimagrumab, with some also receiving semaglutide. The results have been widely discussed, with many researchers anticipating positive outcomes for future obesity treatment strategies.1天前—Expertsbelievetablet versions could prove ... Results of the first phase 3trialcomparing orforglipron with oralsemaglutide... The BELIEVE study specifically targets individuals who are overweight or obese but do not have diabetes, allowing for a focused evaluation of its effects on body composition.

The implications of the BELIEVE trial extend beyond mere weight reduction. The preservation of lean muscle mass is vital for maintaining metabolic rate, physical function, and overall health. Losing significant muscle can lead to a decrease in basal metabolic rate, making it harder to maintain weight loss in the long term and potentially contributing to sarcopenia, the age-related loss of muscle mass. The bimagrumab + semaglutide combination appears to mitigate this risk, offering a more holistic approach to healthNew GLP-1 pill helps patients lose up to 8% of body weight ....

While semaglutide has already demonstrated significant efficacy in weight loss and cardiovascular outcome improvements (as seen in the SELECT trial), the integration of bimagrumab addresses a critical unmet need in optimizing the composition of that weight loss.作者：V Aimelet·2025—...semaglutideand bimagrumab led to a 70% reduction in fat mass without any loss of fat‐free mass. Furthermore, results from theBELIEVEPhase 2btrialshow ... The data emerging from this trial are generating considerable excitement within the medical community, with many anticipating the potential for these findings to reshape obesity treatment paradigms. The BELIEVE trial is a testament to the ongoing innovation in pharmaceutical research, pushing the boundaries of what is possible in managing complex health conditions like obesity. The trial's completion of enrollment at Versanis Bio in June 2023 marked a significant milestone, paving the way for these impactful results to be shared more broadly.BELIEVE spotlights quality and quantity approach to weight ...